ketoconazole | The Medical Letter Inc.

Matching articles for "ketoconazole"

Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

The Medical Letter on Drugs and Therapeutics • April 15, 2024; (Issue 1700)

The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old....

The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication. It is also available in a 0.3% cream formulation (Zoryve) for treatment of plaque psoriasis and in an oral formulation (Daliresp, and generics) for treatment of chronic obstructive pulmonary disease. A 0.15% cream formulation for treatment of atopic dermatitis in patients ≥6 years old will be reviewed by the FDA in July.

Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9 | Show Full Introduction Hide Full Introduction

Osilodrostat (Isturisa) for Cushing's Disease

The Medical Letter on Drugs and Therapeutics • February 8, 2021; (Issue 1617)

The FDA has approved osilodrostat (Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not...

The FDA has approved osilodrostat (Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not an option or has not been curative. Osilodrostat is the first cortisol synthesis inhibitor to be approved in the US for this indication. Other oral steroidogenesis inhibitors such as ketoconazole and metyrapone have been used off-label for this indication for many years.

Med Lett Drugs Ther. 2021 Feb 8;63(1617):21-3 | Show Full Introduction Hide Full Introduction

Advice for Travelers

The Medical Letter on Drugs and Therapeutics • October 7, 2019; (Issue 1582)

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate...

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Oct 7;61(1582):153-60 | Show Full Introduction Hide Full Introduction

A 4-Drug Combination (Viekira Pak) for Hepatitis C

The Medical Letter on Drugs and Therapeutics • February 2, 2015; (Issue 1461)

The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged...

The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged with a third new direct-acting antiviral agent (dasabuvir) in a second tablet, for oral treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US.

Med Lett Drugs Ther. 2015 Feb 2;57(1461):15-7 | Show Full Introduction Hide Full Introduction

Luliconazole Cream (Luzu) for Tinea Infections

The Medical Letter on Drugs and Therapeutics • June 23, 2014; (Issue 1445)

The FDA has approved luliconazole (Luzu Cream, 1% – Valeant) for treatment of tinea pedis, tinea cruris, and tinea corporis...

The FDA has approved luliconazole (Luzu Cream, 1% – Valeant) for treatment of tinea pedis, tinea cruris, and tinea corporis infections.

Med Lett Drugs Ther. 2014 Jun 23;56(1445):50-1 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • August 1, 2012; (Issue 120)

The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious Diseases Society of America (www.idsociety.org).

Treat Guidel Med Lett. 2012 Aug;10(120):61-8 | Show Full Introduction Hide Full Introduction

Mifepristone (Korlym) for Cushing's Syndrome

The Medical Letter on Drugs and Therapeutics • June 11, 2012; (Issue 1392)

The FDA has approved the antiprogestin mifepristone (Korlym – Corcept Therapeutics) for control of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing’s syndrome who have type 2...

The FDA has approved the antiprogestin mifepristone (Korlym – Corcept Therapeutics) for control of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing’s syndrome who have type 2 diabetes/ glucose intolerance and have not responded to, or are not candidates for, surgery. Formerly known as RU 486, mifepristone is also available in a lower strength as Mifeprex for use in terminating an early intrauterine pregnancy.

Med Lett Drugs Ther. 2012 Jun 11;54(1392):46-7 | Show Full Introduction Hide Full Introduction

Drugs for Peptic Ulcer Disease and GERD

The Medical Letter on Drugs and Therapeutics • September 1, 2011; (Issue 109)

Peptic ulcer disease (PUD) is usually caused by nonsteroidal anti-inflammatory drugs (NSAIDs) or by infection with Helicobacter pylori. Gastroesophageal reflux disease (GERD) can be caused by...

Peptic ulcer disease (PUD) is usually caused by nonsteroidal anti-inflammatory drugs (NSAIDs) or by infection with Helicobacter pylori. Gastroesophageal reflux disease (GERD) can be caused by transient lower esophageal sphincter relaxation, reduced lower esophageal sphincter tone, hiatal hernia, delayed gastric emptying or hormonal changes due to pregnancy. Acid suppressive therapy is the cornerstone of management for both PUD and GERD.

Treat Guidel Med Lett. 2011 Sep;9(109):55-60 | Show Full Introduction Hide Full Introduction

New Simvastatin Dosing Recommendations

The Medical Letter on Drugs and Therapeutics • August 8, 2011; (Issue 1370)

The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone (Zocor, and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor).

Med Lett Drugs Ther. 2011 Aug 8;53(1370):61-2 | Show Full Introduction Hide Full Introduction

Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer

The Medical Letter on Drugs and Therapeutics • August 8, 2011; (Issue 1370)

The FDA has approved abiraterone acetate (Zytiga – Centocor Ortho Biotech) for oral treatment, in combination with prednisone, of metastatic castration-resistant prostate cancer in patients previously treated...

The FDA has approved abiraterone acetate (Zytiga – Centocor Ortho Biotech) for oral treatment, in combination with prednisone, of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel (Taxotere, and others). It is the first oral drug approved for this indication. Zytiga will compete with cabazitaxel (Jevtana) and sipuleucel-T (Provenge).

Med Lett Drugs Ther. 2011 Aug 8;53(1370):63-4 | Show Full Introduction Hide Full Introduction

Cost of Topical Products for Tinea Pedis

The Medical Letter on Drugs and Therapeutics • May 3, 2010; (Issue 1337)

A Medical Letter reader recently received a diagnosis of athlete’s foot and a prescription for Naftin gel, for which his pharmacy charged $145, and his insurance company required a $70 copay because this...

A Medical Letter reader recently received a diagnosis of athlete’s foot and a prescription for Naftin gel, for which his pharmacy charged $145, and his insurance company required a $70 copay because this formulation was not included in its formulary. Do patients need to pay prices like these to treat tinea pedis?

Med Lett Drugs Ther. 2010 May 3;52(1337):35-6 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • December 1, 2009; (Issue 88)

The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from...

Treat Guidel Med Lett. 2009 Dec;7(88):95-102 | Show Full Introduction Hide Full Introduction

Aliskiren/Valsartan (Valturna) for Hypertension

The Medical Letter on Drugs and Therapeutics • November 30, 2009; (Issue 1326)

The FDA has approved the use of aliskiren (Tekturna), a direct renin inhibitor, with valsartan (Diovan), an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for treatment...

The FDA has approved the use of aliskiren (Tekturna), a direct renin inhibitor, with valsartan (Diovan), an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for treatment of hypertension in patients already taking both drugs or not adequately controlled on monotherapy, and as initial therapy in those likely to need multiple drugs to control their blood pressure.

Med Lett Drugs Ther. 2009 Nov 30;51(1326):94-5 | Show Full Introduction Hide Full Introduction

Dronedarone (Multaq) for Atrial Fibrillation

The Medical Letter on Drugs and Therapeutics • October 5, 2009; (Issue 1322)

Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but...

Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.

Med Lett Drugs Ther. 2009 Oct 5;51(1322):78-80 | Show Full Introduction Hide Full Introduction

Drugs for Inflammatory Bowel Disease

The Medical Letter on Drugs and Therapeutics • September 1, 2009; (Issue 85)

Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is induction or maintenance of remission. Table 1 on page 66 lists the drugs used to treat IBD with their formulations and cost. Table 2 on page 68 lists the drugs of choice and their doses for different indications. Table 3 on page 71 lists the drugs' adverse effects and recommendations for monitoring. More detailed guidelines are available from the American College of Gastroenterology.

Treat Guidel Med Lett. 2009 Sep;7(85):65-74 | Show Full Introduction Hide Full Introduction

Fesoterodine (Toviaz) for Overactive Bladder

The Medical Letter on Drugs and Therapeutics • May 4, 2009; (Issue 1311)

The FDA has approved the marketing of fesoterodine (Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this...

The FDA has approved the marketing of fesoterodine (Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.

Med Lett Drugs Ther. 2009 May 4;51(1311):34-5 | Show Full Introduction Hide Full Introduction

Drug Interactions with Simvastatin

The Medical Letter on Drugs and Therapeutics • October 20, 2008; (Issue 1297)

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became...

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin (Lipitor) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.

Med Lett Drugs Ther. 2008 Oct 20;50(1297):83-4 | Show Full Introduction Hide Full Introduction

Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension

The Medical Letter on Drugs and Therapeutics • August 25, 2008; (Issue 1293)

Aliskiren (Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide (Tekturna HCT -...

Aliskiren (Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide (Tekturna HCT - Novartis). Many angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are also available in fixed-dose combinations with hydrochlorothiazide (HCTZ).

Med Lett Drugs Ther. 2008 Aug 25;50(1293):65-6 | Show Full Introduction Hide Full Introduction

Which Statin?

The Medical Letter on Drugs and Therapeutics • April 21, 2008; (Issue 1284)

Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much...

Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much lower retail price or lower co-pay than atorvastatin.

Med Lett Drugs Ther. 2008 Apr 21;50(1284):29-31 | Show Full Introduction Hide Full Introduction

Drugs for Lipids

The Medical Letter on Drugs and Therapeutics • February 1, 2008; (Issue 66)

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for lifestyle changes; a combination of diet, exercise and lipid-lowering drugs is optimal for prevention of coronary disease. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoprotein levels return to pretreatment levels in 2-3 weeks.

Treat Guidel Med Lett. 2008 Feb;6(66):9-16 | Show Full Introduction Hide Full Introduction

Ixabepilone (Ixempra) for Breast Cancer

The Medical Letter on Drugs and Therapeutics • January 28, 2008; (Issue 1278)

Ixabepilone (ix ab ep' i lone; Ixempra - Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination...

Ixabepilone (ix ab ep' i lone; Ixempra - Bristol-Myers Squibb), a semisynthetic epothilone analog, has been approved by the FDA for treatment of advanced breast cancer. It is indicated for use in combination with capecitabine (Xeloda - Roche) for treatment of locally advanced or metastatic breast cancer after failure of an anthracycline such as doxorubicin (Adriamycin) and a taxane such as paclitaxel (Taxol, and others). It is also approved as monotherapy for treatment of metastatic or locally advanced breast cancer after an anthracycline, a taxane and capecitabine have failed.

Med Lett Drugs Ther. 2008 Jan 28;50(1278):7-8 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • January 1, 2008; (Issue 65)

The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from...

Treat Guidel Med Lett. 2008 Jan;6(65):1-8 | Show Full Introduction Hide Full Introduction

CYP3A and Drug Interactions

The Medical Letter on Drugs and Therapeutics • July 4, 2005; (Issue 1212)

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.

Med Lett Drugs Ther. 2005 Jul 4;47(1212):54-5 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • February 1, 2005; (Issue 30)

The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the...

The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.

Treat Guidel Med Lett. 2005 Feb;3(30):7-14 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • December 1, 2004; (Issue 28)

Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into treatment of latent infection diagnosed by a positive PPD and treatment of active clinical TB. Guidelines with detailed management recommendations are available from the US Centers for Disease Control and Prevention (CDC) (MMWR Morbid Mortal Wkly Rep 2003; 52RR-11:1).

Treat Guidel Med Lett. 2004 Dec;2(28):83-2 | Show Full Introduction Hide Full Introduction

Safety of Aggressive Statin Therapy

The Medical Letter on Drugs and Therapeutics • November 22, 2004; (Issue 1196)

New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from...

New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.

Med Lett Drugs Ther. 2004 Nov 22;46(1196):93-5 | Show Full Introduction Hide Full Introduction

Telithromycin (Ketek) for Respiratory Infections

The Medical Letter on Drugs and Therapeutics • August 16, 2004; (Issue 1189)

Telithromycin (Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in...

Telithromycin (Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.

Med Lett Drugs Ther. 2004 Aug 16;46(1189):66-8 | Show Full Introduction Hide Full Introduction

Drugs for Parasitic Infections

The Medical Letter on Drugs and Therapeutics • August 16, 2004; (Issue 1189)

Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table below lists first-choice and alternative drugs for most parasitic infections. The brand names and manufacturers of the drugs are listed in this article.

Med Lett Drugs Ther. 2004 Aug 16;46(1189):66 | Show Full Introduction Hide Full Introduction

Topical Sertaconazole (Ertaczo) -- Another Azole for Tinea Pedis

The Medical Letter on Drugs and Therapeutics • June 21, 2004; (Issue 1185)

Sertaconazole nitrate (Ertaczo - OrthoNeutrogena), an imidazole antifungal similar to clotrimazole and miconazole, has been approved by the FDA as a 2% cream for topical treatment of interdigital tinea pedis...

Sertaconazole nitrate (Ertaczo - OrthoNeutrogena), an imidazole antifungal similar to clotrimazole and miconazole, has been approved by the FDA as a 2% cream for topical treatment of interdigital tinea pedis infection. It has been available in Europe for many years.

Med Lett Drugs Ther. 2004 Jun 21;46(1185):50-2 | Show Full Introduction Hide Full Introduction

Drugs for Peptic Ulcers

The Medical Letter on Drugs and Therapeutics • February 1, 2004; (Issue 18)

Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori. The majority of NSAID-related...

Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori. The majority of NSAID-related ulcers are gastric. H. pylori infection causes both duodenal and gastric ulcers. Eradication of H. pylori promotes healing and markedly decreases recurrence of both duodenal and gastric ulcers (A Shiotamni and DY Graham, Med Clin North Am 2002; 86:1447; FKL Chan and WK Leung, Lancet 2002; 360:933). The first step in the management of peptic ulcers is the diagnosis and treatment of H. pylori.

Treat Guidel Med Lett. 2004 Feb;2(18):7-12 | Show Full Introduction Hide Full Introduction

Drugs for HIV

The Medical Letter on Drugs and Therapeutics • January 1, 2004; (Issue 17)

New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV...

Treat Guidel Med Lett. 2004 Jan;2(17):1-6 | Show Full Introduction Hide Full Introduction

Tadalafil (Cialis) for Erectile Dysfunction

The Medical Letter on Drugs and Therapeutics • December 22, 2003; (Issue 1172)

Tadalafil (Cialis - Lilly Icos) is the third oral drug to be approved by the FDA for treatment of erectile dysfunction. It has a longer duration of action than sildenafil (Viagra) or vardenafil (Levitra -...

Tadalafil (Cialis - Lilly Icos) is the third oral drug to be approved by the FDA for treatment of erectile dysfunction. It has a longer duration of action than sildenafil (Viagra) or vardenafil (Levitra - Medical Letter 2003; 45:77).

Med Lett Drugs Ther. 2003 Dec 22;45(1172):101-2 | Show Full Introduction Hide Full Introduction

Vardenafil (Levitra) for Erectile Dysfunction

The Medical Letter on Drugs and Therapeutics • September 29, 2003; (Issue 1166)

Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5 years. Pharmacokinetics, effectiveness, adverse effects, dosage and cost of the new drug are reviewed. Whether it offers any benefits over sildenafil is discussed.

Med Lett Drugs Ther. 2003 Sep 29;45(1166):77-8 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • June 8, 2003; (Issue 1158)

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.

Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 | Show Full Introduction Hide Full Introduction

Xanax XR for Panic Disorder

The Medical Letter on Drugs and Therapeutics • May 26, 2003; (Issue 1157)

The FDA has approved an extended-release (XR) formulation of the benzodiazepine alprazolam (Xanax XR - Pfizer) for treatment of panic disorder, with or without agoraphobia. The new formulation is intended to...

The FDA has approved an extended-release (XR) formulation of the benzodiazepine alprazolam (Xanax XR - Pfizer) for treatment of panic disorder, with or without agoraphobia. The new formulation is intended to reduce the need for frequent dosing and problems of interdose anxiety. This review describes the effectiveness of the extended-release formulation, as well as sections on dependence, abuse and withdrawal, adverse effects, and drug interactions. The review concludes with an overall assessment of the drug's efficacy and cost.

Med Lett Drugs Ther. 2003 May 26;45(1157):43-4 | Show Full Introduction Hide Full Introduction

Eplerenone (Inspra)

The Medical Letter on Drugs and Therapeutics • May 12, 2003; (Issue 1156)

Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of...

Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of hypertension. It has also been tried for treatment of heart failure.

Med Lett Drugs Ther. 2003 May 12;45(1156):39-40 | Show Full Introduction Hide Full Introduction

Eletriptan (Relpax) for Migraine

The Medical Letter on Drugs and Therapeutics • April 28, 2003; (Issue 1155)

Eletriptan hydrobromide (Relpax Pfizer) is now available in the US for oral treatment of migraine headache in adults. It is the seventh serotonin 5-HT1B/1D-receptor agonist (triptan) to be approved by the FDA...

Eletriptan hydrobromide (Relpax Pfizer) is now available in the US for oral treatment of migraine headache in adults. It is the seventh serotonin 5-HT_1B/1D-receptor agonist (triptan) to be approved by the FDA for this indication. This review describes the pharmacokinetics, adverse effects, drug interactions and recommended dosage of eletriptan. Clinical trials comparing the new drug to placebo and to sumatriptan are presented. A dosage and cost table for all the triptans available in the US is also included. The review concludes with an overall assessment of eletriptan's efficacy and safety.

Med Lett Drugs Ther. 2003 Apr 28;45(1155):33-4 | Show Full Introduction Hide Full Introduction

Drugs of Choice for Cancer

The Medical Letter on Drugs and Therapeutics • March 1, 2003; (Issue 7)

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.

Treat Guidel Med Lett. 2003 Mar;1(7):41-52 | Show Full Introduction Hide Full Introduction

Buprenorphine: An alternative to Methadone

The Medical Letter on Drugs and Therapeutics • February 17, 2003; (Issue 1150)

The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only...

The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only for parenteral use in treatment of pain (Buprenex, and others), it offers an alternative to methadone (Dolophine, and others), which is now often abused (New York Times, February 9, 2003; page 1). As a schedule III narcotic, buprenorphine will be subject to fewer prescribing restrictions than a schedule II drug such as methadone (MJ Kreek and FJ Vocci, J Subst Abuse Treat 2002; 23:93).w1150a

Med Lett Drugs Ther. 2003 Feb 17;45(1150):13-5 | Show Full Introduction Hide Full Introduction

Drugs for Parasitic Infections

The Medical Letter on Drugs and Therapeutics • April 1, 2002; (Issue 1127)

Superseded--purchase updated Parasitic Infections article
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites.

Note: Drugs for Parasitic Infections, revised and updated, is now available to both subscribers and nonsubscribers on our web site. This article, a bi-annual feature of The Medical Letter for many years, will not be published as a printed issue in 2002, but is included in the 16th edition of The Medical Letter Handbook of Antimicrobial Therapy. The handbook is now available and can be ordered by calling customer service at 1-800-211-2769.

Med Lett Drugs Ther. 2002 Apr 1;44(1127):32 | Show Full Introduction Hide Full Introduction

Mifepristone (RU 486)

The Medical Letter on Drugs and Therapeutics • October 30, 2000; (Issue 1091)

Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol (Cytotec - Searle),...

Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol (Cytotec - Searle), an E₁ prostaglandin analog marketed in the USA only for prevention of gastric ulcers.

Med Lett Drugs Ther. 2000 Oct 30;42(1091):101-2 | Show Full Introduction Hide Full Introduction

Zonisamide (Zonegran) For Epilepsy

The Medical Letter on Drugs and Therapeutics • October 2, 2000; (Issue 1089)

Zonisamide (Zonegran - Elan Pharma), a sulfonamide chemically unrelated to other antiepileptic drugs, has been approved by the FDA for adjunctive use in adults with partial seizures. Zonisamide has been...

Zonisamide (Zonegran - Elan Pharma), a sulfonamide chemically unrelated to other antiepileptic drugs, has been approved by the FDA for adjunctive use in adults with partial seizures. Zonisamide has been available in Japan for more than 10 years.

Med Lett Drugs Ther. 2000 Oct 2;42(1089):94-5 | Show Full Introduction Hide Full Introduction

Dofetilide for Atrial Fibrillation

The Medical Letter on Drugs and Therapeutics • May 15, 2000; (Issue 1078)

Dofetilide (Tikosyn - Pfizer), a new methanesulfonamide antiarrhythmic drug, has recently been marketed for oral treatment of atrial fibrillation and...

Dofetilide (Tikosyn - Pfizer), a new methanesulfonamide antiarrhythmic drug, has recently been marketed for oral treatment of atrial fibrillation and flutter.

Med Lett Drugs Ther. 2000 May 15;42(1078):41-2 | Show Full Introduction Hide Full Introduction

Sirolimus (Rapamune) for Transplant Rejection

The Medical Letter on Drugs and Therapeutics • February 7, 2000; (Issue 1071)

Sirolimus, whlch is structurally related to tacrolimus, has been approved by the FDA for prevention of acute renal transplant rejection. The manufacturer recommends that sirolimus be taken with cyclosporine and...

Med Lett Drugs Ther. 2000 Feb 7;42(1071):13-4 | Show Full Introduction Hide Full Introduction

Rabeprazole

The Medical Letter on Drugs and Therapeutics • November 19, 1999; (Issue 1066)

Rabeprazole, a benzimidazole proton pump inhibitor similar to omeprazole and lansoprazole, has been approved by the FDA for treatment of duodenal ulcers, healing and maintenance treatment of erosive or ulcerative gastroesophageal reflux disease, and for long-term treatment of chronic hypersecretory conditions, including Zollinger-Ellison syndrome

Med Lett Drugs Ther. 1999 Nov 19;41(1066):110-2 | Show Full Introduction Hide Full Introduction

Drugs for Sexually Transmitted Infections

The Medical Letter on Drugs and Therapeutics • September 24, 1999; (Issue 1062)

Many infections can be transmitted during sexual contact. The text and tables [in this article] are limited to treatment of non-HIV infections associated primarily with sexual...

Many infections can be transmitted during sexual contact. The text and tables [in this article] are limited to treatment of non-HIV infections associated primarily with sexual transmission.

Med Lett Drugs Ther. 1999 Sep 24;41(1062):85-90 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • July 2, 1999; (Issue 1056)

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new...

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2;41(1056):59-62 | Show Full Introduction Hide Full Introduction

Cilostazol for Intermittent Claudication

The Medical Letter on Drugs and Therapeutics • May 7, 1999; (Issue 1052)

Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial...

Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.

Med Lett Drugs Ther. 1999 May 7;41(1052):44-6 | Show Full Introduction Hide Full Introduction

Citalopram for Depression

The Medical Letter on Drugs and Therapeutics • December 4, 1998; (Issue 1041)

Citalopram hydrobromide (Celexa - Forest/Parke-Davis), a selective serotonin reuptake inhibitor (SSRI) available in Europe since 1989, has now been approved by the US Food and Drug Administration (FDA) for...

Citalopram hydrobromide (Celexa - Forest/Parke-Davis), a selective serotonin reuptake inhibitor (SSRI) available in Europe since 1989, has now been approved by the US Food and Drug Administration (FDA) for treatment of depression. It is being advertised as having a 'favorable side-effect profile.'

Med Lett Drugs Ther. 1998 Dec 4;40(1041):113-4 | Show Full Introduction Hide Full Introduction

Sildenafil: An Oral Drug for Impotence

The Medical Letter on Drugs and Therapeutics • May 8, 1998; (Issue 1026)

Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus...

Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus cavemosum (Caverject) or pushed into the urethra (MUSE).

Med Lett Drugs Ther. 1998 May 8;40(1026):51-2 | Show Full Introduction Hide Full Introduction

Sibutramine for Obesity

The Medical Letter on Drugs and Therapeutics • March 13, 1998; (Issue 1022)

Sibutramine hydrochlorid monohydreate (Meridia - Knoll), which is structurally related to amphetamine, has been approved by the FDA for treatment of obesity. It is classified by the Drug Enforcement Agency...

Sibutramine hydrochlorid monohydreate (Meridia - Knoll), which is structurally related to amphetamine, has been approved by the FDA for treatment of obesity. It is classified by the Drug Enforcement Agency (DEA) as a schedule IV controlled substance.

Med Lett Drugs Ther. 1998 Mar 13;40(1022):32 | Show Full Introduction Hide Full Introduction

Cerivastatin for Hypercholesterolemia

The Medical Letter on Drugs and Therapeutics • January 16, 1998; (Issue 1018)

Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl...

Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic acid.

Med Lett Drugs Ther. 1998 Jan 16;40(1018):13-4 | Show Full Introduction Hide Full Introduction

Drugs for Parasitic Infections

The Medical Letter on Drugs and Therapeutics • January 2, 1998; (Issue 1017)

(Superseded by the 2013 version. Click here to purchase.)
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table lists first-choice and alternative drugs for most parasitic infections.

Med Lett Drugs Ther. 1998 Jan 2;40(1017):1-12 | Show Full Introduction Hide Full Introduction

Systemic Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • September 12, 1997; (Issue 1009)

The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the...

The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the FDA.

Med Lett Drugs Ther. 1997 Sep 12;39(1009):86-8 | Show Full Introduction Hide Full Introduction

Topical Butenafine for Tinea Pedis

The Medical Letter on Drugs and Therapeutics • July 4, 1997; (Issue 1004)

Butenafine hydrochloride 1% cream (Mentax - Penederm), a benzylamine antifungal drug similar to the allylamines terbinafine (Lamisil) and naftifine (Naftin), is now available in the USA for topical treatment...

Med Lett Drugs Ther. 1997 Jul 4;39(1004):63-4 | Show Full Introduction Hide Full Introduction

Donepezil (Aricept) for Alzheimer's Disease

The Medical Letter on Drugs and Therapeutics • June 6, 1997; (Issue 1002)

Donepezil hydrochloride (Aricept - Eisai), a piperidine-based acetylcholinesterase inhibitor, is now being marketed for oral treatment of cognitive symptoms in patients with mild to moderate dementia due to...

Donepezil hydrochloride (Aricept - Eisai), a piperidine-based acetylcholinesterase inhibitor, is now being marketed for oral treatment of cognitive symptoms in patients with mild to moderate dementia due to Alzheimer's disease. Donepezil is the second drug approved for this indication; tacrine hydrochloride (Cognex), also an acetylcholinesterase inhibitor, has been available in the USA for four years (Medical Letter, 35:87, 1993).

Med Lett Drugs Ther. 1997 Jun 6;39(1002):53-4 | Show Full Introduction Hide Full Introduction

Atorvastatin - A New Lipid-lowering Drug

The Medical Letter on Drugs and Therapeutics • March 28, 1997; (Issue 997)

Atorvastatin (Lipitor - Parke-Davis), an HMG-CoA reductase inhibitor (or 'statin'), was recently approved by the US Food and Drug Administration for treatment of primary hypercholesterolemia and mixed...

Atorvastatin (Lipitor - Parke-Davis), an HMG-CoA reductase inhibitor (or 'statin'), was recently approved by the US Food and Drug Administration for treatment of primary hypercholesterolemia and mixed dyslipidemia. A single stereoisomer of a pyrrole derivative, the new drug is chemically different from other statins.

Med Lett Drugs Ther. 1997 Mar 28;39(997):29-31 | Show Full Introduction Hide Full Introduction

Drugs for Treatment of Peptic Ulcers

The Medical Letter on Drugs and Therapeutics • January 3, 1997; (Issue 991)

Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are now thought to be associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori. The majority of NSAID-related ulcers are gastric. H. pylori have been associated with both duodenal and gastric ulcers. Eradication of H. pylori promotes healing and markedly decreases recurrence of both duodenal and gastric ulcers (AH Soll, JAMA, 275:622, 1996).

Med Lett Drugs Ther. 1997 Jan 3;39(991):1-4 | Show Full Introduction Hide Full Introduction

Fexofenadine

The Medical Letter on Drugs and Therapeutics • October 25, 1996; (Issue 986)

Fexofenadine (fex oh fen' a deen) hydrochloride (Allegra - Hoechst Marion Roussel) has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. An active metabolite of...

Fexofenadine (fex oh fen' a deen) hydrochloride (Allegra - Hoechst Marion Roussel) has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. An active metabolite of terfenadine, fexofenadine is being heavily advertised as "nonsedating...without 'black box' warnings."

Med Lett Drugs Ther. 1996 Oct 25;38(986):95-6 | Show Full Introduction Hide Full Introduction

Terbinafine for Onychomycosis

The Medical Letter on Drugs and Therapeutics • August 16, 1996; (Issue 981)

Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment...

Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment of fungal nail infections caused by dermatophytes. Oral terbinafine has been available in Europe since 1992.

Med Lett Drugs Ther. 1996 Aug 16;38(981):72-4 | Show Full Introduction Hide Full Introduction

Cetirizine - A New Antihistamine

The Medical Letter on Drugs and Therapeutics • March 15, 1996; (Issue 970)

Cetirizine (Zyrtec - Pfizer), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis, perennial allergic rhinitis and...

Med Lett Drugs Ther. 1996 Mar 15;38(970):21-3 | Show Full Introduction Hide Full Introduction

Systemic Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • February 2, 1996; (Issue 967)

The drugs of choice for treatment of deep fungal infections are listed in the table on page 101. Some of the indications and dosages recommended here have not been approved by the US Food and Drug...

The drugs of choice for treatment of deep fungal infections are listed in the table on page 101. Some of the indications and dosages recommended here have not been approved by the US Food and Drug Administration. More detailed guidelines are available from the Infectious Diseases Society of America (J Sobel et al, Clin Infect Dis, volume 30, April 2000).

Med Lett Drugs Ther. 1996 Feb 2;38(967):10-2 | Show Full Introduction Hide Full Introduction

Itraconazole for Onychomycosis

The Medical Letter on Drugs and Therapeutics • January 19, 1996; (Issue 966)

Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.

Med Lett Drugs Ther. 1996 Jan 19;38(966):5-6 | Show Full Introduction Hide Full Introduction

Drugs for AIDS and Associated Infections

The Medical Letter on Drugs and Therapeutics • October 13, 1995; (Issue 959)

Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with...

Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with AIDS.

Med Lett Drugs Ther. 1995 Oct 13;37(959):87-94 | Show Full Introduction Hide Full Introduction

Drugs For Tuberculosis

The Medical Letter on Drugs and Therapeutics • August 4, 1995; (Issue 954)

Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most important cause of treatment failure and is associated with emergence of drug resistence, some experts now recommend that all patients take drugs for TB under direct observation (SE Weis et al, N Engl J Med, 330:1179, 1994; R Bayer and D Wilkinson, Lancet, 345:1545, June 17, 1995).

Med Lett Drugs Ther. 1995 Aug 4;37(954):67-70 | Show Full Introduction Hide Full Introduction

Tacrolimus FK506 Organ Transplants

The Medical Letter on Drugs and Therapeutics • September 16, 1994; (Issue 931)

Tacrolimus (Prograf - Fujisawa), previously called FK506 (Medical Letter, 33:94, 1991), has been approved by the US Food and Drug Administration for primary prevention of organ rejection in patients receiving...

Tacrolimus (Prograf - Fujisawa), previously called FK506 (Medical Letter, 33:94, 1991), has been approved by the US Food and Drug Administration for primary prevention of organ rejection in patients receiving liver transplants. The drug has also been used as rescue therapy for organ graft rejection unresponsive to cyclosporine (Sandimmune) and other immunosuppressive drugs.

Med Lett Drugs Ther. 1994 Sep 16;36(931):82-3 | Show Full Introduction Hide Full Introduction

Drugs for Treatment of Peptic Ulcers

The Medical Letter on Drugs and Therapeutics • July 22, 1994; (Issue 927)

Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are now thought to be associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori (NIH Consensus Development Panel, JAMA, 272:65, July 6, 1994). NSAID-related ulcers are usually gastric. H. pylori have been associated with both duodenal and gastric ulcers.

Med Lett Drugs Ther. 1994 Jul 22;36(927):65-7 | Show Full Introduction Hide Full Introduction

LAAM - Long-Acting Methadone for Treatment of Heroin Addiction

The Medical Letter on Drugs and Therapeutics • June 10, 1994; (Issue 924)

Methadone, an opioid agonist that can be taken orally, has been used for maintenance treatment for many years in the USA (DM Novick et al, Drug Alcohol Depend, 33:235, 1993). Last year, the US Food and Drug Administration approved the distribution and use of L-alpha-acetyl-methadol (LAAM; ORLAAM - Bio Development Corporation, McLean, VA), a long-acting congener of methadone. LAAM, like methadone, will be available for this indication only through federal and state-regulated treatment programs.

Med Lett Drugs Ther. 1994 Jun 10;36(924):52 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • October 29, 1993; (Issue 908)

The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).

Med Lett Drugs Ther. 1993 Oct 29;35(908):99-102 | Show Full Introduction Hide Full Introduction

Drugs for AIDS and Associated infections

The Medical Letter on Drugs and Therapeutics • September 3, 1993; (Issue 904)

Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with...

Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with AIDS.

Med Lett Drugs Ther. 1993 Sep 3;35(904):79-86 | Show Full Introduction Hide Full Introduction

Topical Terbinafine for Tinea Infections

The Medical Letter on Drugs and Therapeutics • August 20, 1993; (Issue 903)

Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of...

Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of tinea pedis, tinea cruris, and tinea corporis infections. An oral formulation is available in Europe and is under investigation here.

Med Lett Drugs Ther. 1993 Aug 20;35(903):76-8 | Show Full Introduction Hide Full Introduction

Loratadine - A New Antihistamine

The Medical Letter on Drugs and Therapeutics • August 6, 1993; (Issue 902)

Loratadine (Claritin - Schering), a new H 1 -receptor antagonist, has been approved by the U.S. Food and Drug Administration for treatment of seasonal allergic rhinitis in patients more than 12 years old. It...

Loratadine (Claritin - Schering), a new H 1 -receptor antagonist, has been approved by the U.S. Food and Drug Administration for treatment of seasonal allergic rhinitis in patients more than 12 years old. It will compete with older, relatively sedating drugs such as chlorpheniramine (Chlor-Trimeton, and others) and clemastine (Tavist - Medical Letter, 35:9, 1993) and with newer relatively non-sedating agents such as terfenadine (Seldane) and astemizole (Hismanal).

Med Lett Drugs Ther. 1993 Aug 6;35(902):71-2 | Show Full Introduction Hide Full Introduction

Paclitaxel (Taxol) for Ovarian Cancer

The Medical Letter on Drugs and Therapeutics • May 14, 1993; (Issue 896)

Paclitaxel (Taxol - Bristol-Myers Squibb) is now available in the USA for treatment of metastatic ovarian cancer refractory to other drugs. The new drug is a natural product extracted in small amounts from...

Paclitaxel (Taxol - Bristol-Myers Squibb) is now available in the USA for treatment of metastatic ovarian cancer refractory to other drugs. The new drug is a natural product extracted in small amounts from the inner bark of the Western yew tree found mainly in the Pacific northwest (Taxus brevifolia). Efforts to synthesize the drug have been unsuccessful to date, but a semi-synthetic product (taxotere) prepared from the needles of European yews has shown some promise (R Pazdur et al, J Natl Cancer Inst, 89:1781, 1992), and a fungus (Taxomyces andreanae) growing on the Pacific yew was recently found to produce paclitaxel even after removal from the tree (A Stierle et al, Science, 260:214, April 9, 1993). In any case, supply of the drug is currently keeping up with demand.

Med Lett Drugs Ther. 1993 May 14;35(896):39-40 | Show Full Introduction Hide Full Introduction

Itraconazole

The Medical Letter on Drugs and Therapeutics • January 22, 1993; (Issue 888)

Itraconazole (Sporanox - Janssen), an antifungal triazole, has been approved by the US Food and Drug Administration (FDA) for oral treatment of histoplasmosis and blastomycosis. These two endemic mycoses...

Itraconazole (Sporanox - Janssen), an antifungal triazole, has been approved by the US Food and Drug Administration (FDA) for oral treatment of histoplasmosis and blastomycosis. These two endemic mycoses occur both in normal hosts and in immunocompromised patients, such as those with AIDS (RW Bradsher, Clin Infect Dis, 14:S82, 1992; LJ Wheat, Clin Infect Dis, 14:S91, 1992).

Med Lett Drugs Ther. 1993 Jan 22;35(888):7-9 | Show Full Introduction Hide Full Introduction

New Advertisement for An Old Antihistamine

The Medical Letter on Drugs and Therapeutics • January 22, 1993; (Issue 888)

Advertisements for clemastine (Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24,...

Advertisements for clemastine (Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24, 1979) that has now become available without a prescription.

Med Lett Drugs Ther. 1993 Jan 22;35(888):9-10 | Show Full Introduction Hide Full Introduction

Drugs For Treatment Of Fungal Infections

The Medical Letter on Drugs and Therapeutics • February 21, 1992; (Issue 864)

The incidence of opportunistic fungal infections continues to increase, particularly in patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units. Intravenous (IV) amphotericin B (Fungizone, and others), sometimes given with flucytosine (Ancobon), is the drug of choice for initial treatment of most rapidly progressive, acutely life-threatening fungal infections; for less severe infections, fluconazole (Diflucan, ketoconazole (Nizoral), or itraconazole (Sporanox - an investigational drug in the (USA) may also be effective, can be taken orally, and are much better tolerated. The treatment of superficial fungal infections is not discussed here.

Med Lett Drugs Ther. 1992 Feb 21;34(864):14-6 | Show Full Introduction Hide Full Introduction

Safety of Terfenadine and Astemizole

The Medical Letter on Drugs and Therapeutics • February 7, 1992; (Issue 863)

Terfenadine (Seldane - Marion Merrell Dow) and astemizole (Hismanal - Janssen) are nonsedating antihistamines widely used to treat symptoms of allergic rhinitis (Medical Letter, 27:65, 1985; 31:43, 1989)....

Terfenadine (Seldane - Marion Merrell Dow) and astemizole (Hismanal - Janssen) are nonsedating antihistamines widely used to treat symptoms of allergic rhinitis (Medical Letter, 27:65, 1985; 31:43, 1989). Both are available without a prescription in Canada, and the US Food and Drug Administration is apparently considering terfenadine for over-the-counter availability in the USA.

Med Lett Drugs Ther. 1992 Feb 7;34(863):9-10 | Show Full Introduction Hide Full Introduction

Drugs For AIDS And Associated Infections

The Medical Letter on Drugs and Therapeutics • October 18, 1991; (Issue 855)

A growing number of clinical trials now permits some consensus on the treatment of human immunodeficiency virus (HIV) and other infections associated with acquired immune deficiency syndrome (AIDS) in...

Med Lett Drugs Ther. 1991 Oct 18;33(855):95-102 | Show Full Introduction Hide Full Introduction

Drugs for Treatment of Fungal Infections

The Medical Letter on Drugs and Therapeutics • June 15, 1990; (Issue 820)

...

Med Lett Drugs Ther. 1990 Jun 15;32(820):58-60 | Show Full Introduction Hide Full Introduction

Fluconazole

The Medical Letter on Drugs and Therapeutics • May 18, 1990; (Issue 818)

Fluconazole (Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of...

Fluconazole (Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of candidiasis. Both cryptococcal meningitis and candidiasis occur frequently in patients with AIDS, organ transplants, or cancer.

Med Lett Drugs Ther. 1990 May 18;32(818):50-2 | Show Full Introduction Hide Full Introduction

Naftifine For Fungal Skin Infections

The Medical Letter on Drugs and Therapeutics • October 21, 1988; (Issue 777)

Naftifine hydrochloride 1% cream (Naftin - Herbert Laboratories), was recently approved by the US Food and Drug Administration (FDA) for topical treatment of tinea cruris and tinea corporis. It is available...

Naftifine hydrochloride 1% cream (Naftin - Herbert Laboratories), was recently approved by the US Food and Drug Administration (FDA) for topical treatment of tinea cruris and tinea corporis. It is available only by prescription.

Med Lett Drugs Ther. 1988 Oct 21;30(777):98-9 | Show Full Introduction Hide Full Introduction

Drugs For Treatment of Deep Fungal Infections

The Medical Letter on Drugs and Therapeutics • March 11, 1988; (Issue 761)

The incidence of opportunistic deep fungal infections continues to increase, particularly among patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care...

The incidence of opportunistic deep fungal infections continues to increase, particularly among patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units.

Med Lett Drugs Ther. 1988 Mar 11;30(761):30-2 | Show Full Introduction Hide Full Introduction